An observational study in Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia and Hypercholesterolemia, sponsored by Verve Therapeutics, Inc.. Enrolling by invitation at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Verve Therapeutics, Inc. (part of Eli Lilly and Company) · Observational
LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. Participants will be followed for a total of 15 years after the first administration of the gene-editing therapy.
1,517 studies on the registry are indexed under Atherosclerosis; 224 are open to participants now.
This study's planned enrollment of 116 is below the median of 250 across 527 observational studies indexed under Atherosclerosis.
Browse Atherosclerosis studies →Verve Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
First submitted before Verve Therapeutics, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Participants who received an investigational gene-editing therapy developed by the sponsor.
Inclusion Criteria
Exclusion Criteria: N/A
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incidence of treatment-related adverse events (AEs), serious adverse events (SAEs) and other events of interest using CTCAE 5.0 to assess the long-term safety of gene-editing therapies.
To assess the long-term safety of gene-editing therapies, the following will be assessed: Incidence of treatment-related adverse events (AEs), serious adverse events (SAEs) and any CTCAE grade 3 or higher AEs.
Time frame: up to 15 years
Percent and absolute change from baseline of lipid concentrations over time after administration of a gene-editing therapy.
Blood samples will be collected to assess percent change from baseline in lipid concentrations (including LDL-C).
Time frame: up to 15 years
Percent and absolute change from baseline of target biomarkers over time after administration of a gene-editing therapy.
Blood samples will be collected to assess percent change from baseline in target biomarkers.
Time frame: up to 15 years
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Oct 2039, 184 months after the start.
Of 169 observational studies under Atherosclerosis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 153. This study's planned 184 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.